Cargando…
Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis
BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation. METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised stu...
Autores principales: | , , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768450/ https://www.ncbi.nlm.nih.gov/pubmed/19773751 http://dx.doi.org/10.1038/sj.bjc.6605333 |
_version_ | 1782173468913041408 |
---|---|
author | Fluge, Ø Gravdal, K Carlsen, E Vonen, B Kjellevold, K Refsum, S Lilleng, R Eide, T J Halvorsen, T B Tveit, K M Otte, A P Akslen, L A Dahl, O |
author_facet | Fluge, Ø Gravdal, K Carlsen, E Vonen, B Kjellevold, K Refsum, S Lilleng, R Eide, T J Halvorsen, T B Tveit, K M Otte, A P Akslen, L A Dahl, O |
author_sort | Fluge, Ø |
collection | PubMed |
description | BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation. METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy. RESULTS: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon cancer, strong EZH2 expression (P=0.041) and high proliferation (⩾40%; P=0.001) were both associated with better relapse-free survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved RFS in colon cancer patients who received adjuvant chemotherapy (P=0.001), but not among those who were treated by surgery alone (P=0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with high proliferation (P=0.046), but not in patients with low proliferation (P=0.26). Multivariate analyses of colon cancers showed that stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high proliferation indicated improved RFS (HR 0.55). CONCLUSION: Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer, but not so in rectal cancer. |
format | Text |
id | pubmed-2768450 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-27684502010-10-20 Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis Fluge, Ø Gravdal, K Carlsen, E Vonen, B Kjellevold, K Refsum, S Lilleng, R Eide, T J Halvorsen, T B Tveit, K M Otte, A P Akslen, L A Dahl, O Br J Cancer Clinical Study BACKGROUND: Enhancer of zeste homologue 2 (EZH2) is a member of the Polycomb group of genes that is involved in epigenetic silencing and cell cycle regulation. METHODS: We studied EZH2 expression in 409 patients with colorectal cancer stages II and III. The patients were included in a randomised study, and treated with surgery alone or surgery followed by adjuvant chemotherapy. RESULTS: EZH2 expression was significantly related to increased tumour cell proliferation, as assessed by Ki-67 expression. In colon cancer, strong EZH2 expression (P=0.041) and high proliferation (⩾40%; P=0.001) were both associated with better relapse-free survival (RFS). In contrast, no such associations were found among rectal cancers. High Ki-67 staining was associated with improved RFS in colon cancer patients who received adjuvant chemotherapy (P=0.001), but not among those who were treated by surgery alone (P=0.087). In colon cancers stage III, a significant association between RFS and randomisation group was found in patients with high proliferation (P=0.046), but not in patients with low proliferation (P=0.26). Multivariate analyses of colon cancers showed that stage III (hazard ratio (HR) 4.00) and high histological grade (HR 1.80) were independent predictors of reduced RFS, whereas high proliferation indicated improved RFS (HR 0.55). CONCLUSION: Strong EZH2 expression and high proliferation are associated features and both indicate improved RFS in colon cancer, but not so in rectal cancer. Nature Publishing Group 2009-10-20 2009-09-22 /pmc/articles/PMC2768450/ /pubmed/19773751 http://dx.doi.org/10.1038/sj.bjc.6605333 Text en Copyright © 2009 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Fluge, Ø Gravdal, K Carlsen, E Vonen, B Kjellevold, K Refsum, S Lilleng, R Eide, T J Halvorsen, T B Tveit, K M Otte, A P Akslen, L A Dahl, O Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis |
title | Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis |
title_full | Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis |
title_fullStr | Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis |
title_full_unstemmed | Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis |
title_short | Expression of EZH2 and Ki-67 in colorectal cancer and associations with treatment response and prognosis |
title_sort | expression of ezh2 and ki-67 in colorectal cancer and associations with treatment response and prognosis |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768450/ https://www.ncbi.nlm.nih.gov/pubmed/19773751 http://dx.doi.org/10.1038/sj.bjc.6605333 |
work_keys_str_mv | AT flugeø expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT gravdalk expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT carlsene expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT vonenb expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT kjellevoldk expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT refsums expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT lillengr expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT eidetj expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT halvorsentb expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT tveitkm expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT otteap expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT akslenla expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis AT dahlo expressionofezh2andki67incolorectalcancerandassociationswithtreatmentresponseandprognosis |